Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

256
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
256
Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

15.1K
Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
15.1K
Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

4.5K
4.5K
Feedback Inhibition00:46

Feedback Inhibition

57.1K
Biochemical reactions are occurring constantly in cells, converting starting substances to different products, usually with the help of enzymes that speed the reactions. Without enzymes, it would take far too long for most reactions to occur to be useful to the cell!
57.1K
Molecules and Compounds02:38

Molecules and Compounds

68.5K
Atoms and Molecules
68.5K
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

18.4K
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
18.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

COVID-19: Failure of the DisCoVeRy Clinical Trial, and Now-New Hopes?

Pharmaceuticals (Basel, Switzerland)·2021
Same author

COVID-19: An Update About the Discovery Clinical Trial.

Pharmaceuticals (Basel, Switzerland)·2020
Same author

Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes-6.

Molecules (Basel, Switzerland)·2020
Same author

2019: An Awesome Year for <i>Pharmaceuticals</i>.

Pharmaceuticals (Basel, Switzerland)·2020
Same author

Tafenoquine: A 2018 Novel FDA-Approved Prodrug for the Radical Cure of <i>Plasmodium vivax</i> Malaria and Prophylaxis of Malaria.

Pharmaceuticals (Basel, Switzerland)·2019
Same author

Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes-5.

Molecules (Basel, Switzerland)·2019

Related Experiment Video

Updated: Jan 27, 2026

The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression
10:29

The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression

Published on: November 12, 2010

40.5K

Baricitinib: A 2018 Novel FDA-Approved Small Molecule Inhibiting Janus Kinases.

Annie Mayence1, Jean Jacques Vanden Eynde2

  • 1Haute Ecole Provinciale de Hainaut-Condorcet, 7330 Saint-Ghislain, Belgium. annie.mayence@alumini.umons.ac.be.

Pharmaceuticals (Basel, Switzerland)
|March 16, 2019
PubMed
Summary

This study details two methods for preparing Baricitinib, a drug approved for rheumatoid arthritis that targets Janus kinases (JAK). These preparation routes are crucial for making the medication available for patients.

Keywords:
FDAJanus kinasesapproved drugsbaricitinibprotein kinase inhibitorrheumatoid arthritis

More Related Videos

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells
10:03

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells

Published on: August 1, 2013

17.6K
Enhancing the Engraftment of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes via a Transient Inhibition of Rho Kinase Activity
08:00

Enhancing the Engraftment of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes via a Transient Inhibition of Rho Kinase Activity

Published on: July 10, 2019

6.6K

Related Experiment Videos

Last Updated: Jan 27, 2026

The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression
10:29

The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression

Published on: November 12, 2010

40.5K
Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells
10:03

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells

Published on: August 1, 2013

17.6K
Enhancing the Engraftment of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes via a Transient Inhibition of Rho Kinase Activity
08:00

Enhancing the Engraftment of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes via a Transient Inhibition of Rho Kinase Activity

Published on: July 10, 2019

6.6K

Area of Science:

  • Pharmacology
  • Medicinal Chemistry
  • Drug Development

Background:

  • Baricitinib, approved in 2018 by the FDA, is a Janus kinase (JAK) inhibitor used for rheumatoid arthritis treatment.
  • Understanding the synthesis of Baricitinib is essential for its availability and further research.

Purpose of the Study:

  • To outline the synthetic procedures for Baricitinib.
  • To present two distinct and viable routes for drug preparation.

Main Methods:

  • The study describes the step-by-step preparation of Baricitinib.
  • Two alternative synthetic pathways were investigated and documented.

Main Results:

  • Successful preparation of Baricitinib was achieved through two distinct chemical routes.
  • Detailed protocols for each preparation method are provided.

Conclusions:

  • The presented synthetic routes offer viable options for Baricitinib preparation.
  • This work supports the accessibility of Baricitinib for therapeutic use and research.